Receiver-operating characteristic analysis of two SmD peptide-based anti-Sm antibody assays

<p><b>Copyright information:</b></p><p>Taken from "Effect of dsDNA binding to SmD-derived peptides on clinical accuracy in the diagnosis of systemic lupus erythematosus"</p><p>http://arthritis-research.com/content/9/4/R68</p><p>Arthritis Research & Therapy 2007;9(4):R68-R68.</p><p>Published online 18 Jul 2007</p><p>PMCID:PMC2206372.</p><p></p> The results of this comparative study were used to generate receiver-operating characteristic curves. The discrimination between systemic lupus erythematosus patient samples and control samples was similar for both SmD immunoassays

Frequency of serum autoantibodies to 21 autoantigens in 100 French Canadian patients with autoimmune myositis

<p><b>Copyright information:</b></p><p>Taken from "Heterogeneity of autoantibodies in 100 patients with autoimmune myositis: insights into clinical features and outcomes"</p><p>http://arthritis-research.com/content/9/4/R78</p><p>Arthritis Research & Therapy 2007;9(4):R78-R78.</p><p>Published online 9 Aug 2007</p><p>PMCID:PMC2206383.</p><p></p> Autoantibodies were observed to 19 (90%) of the specificities tested. Anti-OJ and anti-EJ (both anti-synthetases) were not detected. One or more autoantibodies were present in 80% of patients. Autoantibodies to synthetases (Jo-1, PL-7, PL-12, and KS) and systemic sclerosis autoantibodies were present overall in 22% and 9% of patients, respectively. The overall frequency is over 100% because 44% of patients had more than one autoantibody. Anti-Ro were determined by ALBIA whereas anti-Ro52 and anti-Ro60 fine specificities were identified by ELISA. See Materials and methods (in the text) for a description of immunoasssays. ALBIA, addressable laser bead immunoassay; CENP, centromere protein; ELISA, enzyme-linked immunosorbent assay; RNAPOLIII, RNA polymerase III; SRP, signal recognition particle; TOPO, topoisomerase I